Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding
Daré Bioscience has reached a milestone of over $43 million in non-dilutive grant funding as its investigational programmable drug delivery platform continues to advance.
Stocks · News reference
Daré Bioscience CEO to Present at Stifel's 2026 Healthcare Conference
Daré Bioscience announced that its Founder, President, and CEO, Sabrina Martucci Johnson, will present at the upcoming Stifel 2026 Healthcare Conference.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Daré Bioscience Receive Additional $1.5M Funding Installment Under Grant Agreement For DARE-LARC1
Daré Bioscience Participates in Virtual Investor Discussion on Women's Health Executive Order
Daré Bioscience participated in a virtual investor segment to discuss the implications of a recent executive order focused on advancing research and care for women's health.
Daré Bioscience Announces Presentation on DARE-IDDS at PODD 2026 Conference
Daré Bioscience announced that its Vice President of Product Development, Liz Proos, will present on the company's investigational DARE-IDDS platform at the 16th annual Partnership Opportunities in Drug Delivery (PODD) conference.
Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001401914/000140191426000052/dare-20260928.htm